MOLECULAR PARTNERS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.781 USD | +2.19% |
|
-2.55% | -9.54% |
| Sales 2024 * | 13.86M 15.06M | Sales 2025 * | 18.66M 20.28M | Capitalization | 108M 118M |
|---|---|---|---|---|---|
| Net income 2024 * | -59M -64.11M | Net income 2025 * | -61M -66.29M | EV / Sales 2024 * | 7.8 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.79 x |
| P/E ratio 2024 * |
-1.94
x | P/E ratio 2025 * |
-1.77
x | Employees | 168 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on Molecular Partners AG
More recommendations
More press releases
| 1 day | +2.19% | ||
| 1 week | -2.55% | ||
| 1 month | -9.98% | ||
| 3 months | -20.90% | ||
| 6 months | +7.11% | ||
| Current year | -9.54% |
1 week
3.60
3.97
1 month
3.324.90
Current year
3.325.08
1 year
3.327.32
3 years
3.3232.04
5 years
3.3232.04
10 years
3.3232.04
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 52 | 04-11-22 | |
Patrick Amstutz
FOU | Founder | 49 | 04-11-22 |
Michael Pitzner
CMP | Compliance Officer | - | 22-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
William Burns
CHM | Chairman | 76 | 17-10-30 |
Steven Holtzman
BRD | Director/Board Member | 70 | 14-09-18 |
Vito Palombella
BRD | Director/Board Member | 61 | 20-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 3.781 | +2.19% | 4,726 |
| 24-04-29 | 3.7 | -4.64% | 2,558 |
| 24-04-26 | 3.88 | -.--% | 254 |
Delayed Quote Nasdaq, April 30, 2024 at 04:30 pm EDT
More quotes
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.29
CHF
Average target price
9.35
CHF
Spread / Average Target
+184.19%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.46% | 102B | |
| +1.41% | 96.29B | |
| +2.13% | 22.18B | |
| -15.84% | 21.2B | |
| -9.21% | 18.31B | |
| -39.98% | 17.38B | |
| -14.65% | 16.36B | |
| +4.39% | 13.97B | |
| +31.35% | 12.17B |
- Stock Market
- Equities
- MOLN Stock
- MOLN Stock
